KAPA · Kairos Pharma, LTD.
Substantial doubt about the company's ability to continue as a going concern.
“The Company has experienced recurring losses from operations since inception and incurred a net loss of $3,042 and used cash in operations of $2,048 during the six months ended June 30, 2026. These factors raise substantial doubt about the Company's ability to continue as a going concern. In addition, the Company's independent registered public accounting firm, in its report on the Company's December 31, 2025 financial statements, has expressed substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| $2.45M | $2.14M | $414K | $82K | |
| $3.51M | $3.44M | $1.93M | $1.63M | |
| $142K | $160K | $160K | $160K | |
| $5.96M | $5.57M | $2.34M | $1.71M | |
| -$5.96M | -$5.57M | -$2.34M | -$1.71M | |
| — | — | $35K | $42K | |
| $152K | $125K | -$260K | -$98K | |
| -$5.81M | -$5.45M | -$2.6M | -$1.81M | |
| USD/shares | -$0.28 | -$0.30 | -$0.23 | -$0.17 |
| USD/shares | -$0.28 | -$0.30 | -$0.23 | -$0.17 |
| shares | — | 18.43M | 11.36M | 10.38M |
| shares | — | 18.43M | 11.36M | 10.38M |
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 164 similar-size Biotechnology companies (of 524 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| Item Four | $50,000,000 | $50,000,000 |
| Item One Two and Three | $5,000,000 | — |
| Item One and Two | — | $5,000,000 |